Publikasi Scopus 2024 per tanggal 31 Juli 2024 (607 artikel)

Tarwadi; Pambudi S.; Sriherwanto C.; Sasangka A.N.; Bowolaksono A.; Wijayadikusumah A.R.; Zeng W.; Rachmawati H.; Kartasasmita R.E.; Kazi M.
Tarwadi (24169949500); Pambudi, Sabar (37115903900); Sriherwanto, Catur (57217729443); Sasangka, Ayu N. (59230814400); Bowolaksono, Anom (57205093224); Wijayadikusumah, Acep R. (57194976916); Zeng, Weiguang (7203023746); Rachmawati, Heni (8601757900); Kartasasmita, Rahmana E. (7801610135); Kazi, Mohsin (56921753300)
24169949500; 37115903900; 57217729443; 59230814400; 57205093224; 57194976916; 7203023746; 8601757900; 7801610135; 56921753300
Inclusion of TAT and NLS sequences in lipopeptide molecules generates homogenous nanoparticles for gene delivery applications
2024
International Journal of Pharmaceutics
662
124492
0
Research Center for Vaccines and Drugs, National Agency for Research and Innovation (BRIN), Building 610-611 Puspiptek Area, Banten, Tangerang Selatan, 15314, Indonesia; PT Indomabs Biosantika Utama, Gedung Technology Business and Innovation Centre (TBIC), Pengasinan, Gunung Sindur, Kabupaten Bogor, Jawa Barat, 16340, Indonesia; Research Centre for Applied Microbiology, National Agency for Research and Innovation (BRIN), Building 610-611 Puspiptek Area, Banten, Tangerang Selatan, 15314, Indonesia; Biomedical Sciences, Faculty of Medicine, Universitas Indonesia, Jawa Barat, Depok, 16424, Indonesia; Department of Biology, Faculty of Mathematics and Natural Sciences, Universitas Indonesia, Jawa Barat, Depok, 16424, Indonesia; Research and Development Division, PT. Bio Farma, Jl. Pasteur No 28 Bandung, Jawa Barat, 40161, Indonesia; Peter Doherty Institute, The University of Melbourne, 792 Elizabeth St, Melbourne, 3000, VIC, Australia; School of Pharmacy, Bandung Institute of Technology, Jl. Ganesa 10 Bandung, Jawa Barat, 40132, Indonesia; Research Centre of Nano Sciences and Nanotechnology, Bandung Institute of Technology, Jl. Ganesa 10 Bandung 40132, Jawa Barat, Indonesia; Department of Pharmaceutics, College of Pharmacy, POBOX-2457, King Saud University, Riyadh, 11451, Saudi Arabia
Tarwadi, Research Center for Vaccines and Drugs, National Agency for Research and Innovation (BRIN), Building 610-611 Puspiptek Area, Banten, Tangerang Selatan, 15314, Indonesia, PT Indomabs Biosantika Utama, Gedung Technology Business and Innovation Centre (TBIC), Pengasinan, Gunung Sindur, Kabupaten Bogor, Jawa Barat, 16340, Indonesia; Pambudi S., Research Center for Vaccines and Drugs, National Agency for Research and Innovation (BRIN), Building 610-611 Puspiptek Area, Banten, Tangerang Selatan, 15314, Indonesia; Sriherwanto C., Research Centre for Applied Microbiology, National Agency for Research and Innovation (BRIN), Building 610-611 Puspiptek Area, Banten, Tangerang Selatan, 15314, Indonesia; Sasangka A.N., Biomedical Sciences, Faculty of Medicine, Universitas Indonesia, Jawa Barat, Depok, 16424, Indonesia; Bowolaksono A., Department of Biology, Faculty of Mathematics and Natural Sciences, Universitas Indonesia, Jawa Barat, Depok, 16424, Indonesia; Wijayadikusumah A.R., Research and Development Division, PT. Bio Farma, Jl. Pasteur No 28 Bandung, Jawa Barat, 40161, Indonesia; Zeng W., Peter Doherty Institute, The University of Melbourne, 792 Elizabeth St, Melbourne, 3000, VIC, Australia; Rachmawati H., School of Pharmacy, Bandung Institute of Technology, Jl. Ganesa 10 Bandung, Jawa Barat, 40132, Indonesia, Research Centre of Nano Sciences and Nanotechnology, Bandung Institute of Technology, Jl. Ganesa 10 Bandung 40132, Jawa Barat, Indonesia; Kartasasmita R.E., School of Pharmacy, Bandung Institute of Technology, Jl. Ganesa 10 Bandung, Jawa Barat, 40132, Indonesia; Kazi M., Department of Pharmaceutics, College of Pharmacy, POBOX-2457, King Saud University, Riyadh, 11451, Saudi Arabia
Purposes: The objective of this study is to develop a versatile gene carrier based on lipopeptides capable of delivering genetic material into target cells with minimal cytotoxicity. Methods: Two lipopeptide molecules, palmitoyl-CKKHH and palmitoyl-CKKHH-YGRKKRRQRRR-PKKKRKV, were synthesized using solid phase peptide synthesis and evaluated as transfection agents. Physicochemical characterization of the lipopeptides included a DNA shift mobility assay, particle size measurement, and transmission electron microscopy (TEM) analysis. Cytotoxicity was assessed in CHO-K1 and HepG2 cells using the MTT assay, while transfection efficiency was determined by evaluating the expression of the green fluorescent protein-encoding gene. Results: Our findings demonstrate that the lipopeptides can bind, condense, and shield DNA from DNase degradation. The inclusion of the YGRKKRRQRRR sequence, a transcription trans activator, and the PKKKRKV sequence, a nuclear localization signal, imparts desirable properties. Lipopeptide-based TAT-NLS/DNA nanoparticles exhibited stability for up to 20 days when stored at 6–8 °C, displaying uniformity with a compact size of approximately 120 nm. Furthermore, the lipopeptides exhibited lower cytotoxicity compared to the poly-L-lysine. Transfection experiments revealed that protein expression mediated by the lipopeptide occurred at a charge ratio ranging from 4.0 to 8.0. Conclusion: These results indicate that the lipopeptide, composed of a palmitoyl alkyl chain and TAT and NLS sequences, can efficiently condense and protect DNA, form stable and uniform nanoparticles, and exhibit promising characteristics as a potential gene carrier with minimal cytotoxicity. © 2024 Elsevier B.V.
Cytotoxicity; Homogenous nanoparticle; Lipopeptide; NLS; TAT; Transfection
King Saud University, KSU; Agency for Research and Innovation; University of Melbourne, UNIMELB, (12/II.7/HK/2023); BRIN, (RSP2024R301)
We extend our gratitude to Professor David Jackson for his invaluable contribution to lipopeptide synthesis conducted at the Peter Doherty Institute Laboratory, The University of Melbourne, Australia. We also express our appreciation to the support of Research and Innovation Program for Advancement of Indonesia (RIIM) Project Number of 12/II.7/HK/2023 at the Agency for Research and Innovation (BRI
Elsevier B.V.
3785173
Article
Q1
906
4937